Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (1179)	3/2/1998 9:28:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 2173

There are over 32 million AMLN shares outstanding. News came out after the close. Tomorrow will not be pretty. I'm sure that if you would buy AMLN for $5 (or $3) tomorrow, the line of interested shareholders would be very long.

To: jbershad who wrote (1179)	3/2/1998 9:51:00 PM
From: Tiger	Respond to of 2173

Outstanding shares over 32 million. Book value is not relevant as R&D expenses were not capitalized. A more meaningful number might be R&D$ Spent Per Share. However, R&D spent would not worth anything if the resulting work is not successful. Pramlintide seems to be still alive (at least as reflected in the press release). With the huge amount of research and clinical work completed on pramlintide, the risk/reward ratio actually looks pretty good at the current low price level (and getting lower tomorrow). This will be a big winner if the drugs works (where else can one find a company with multiple ongoing Phase III trials of a blockbuster drug at a price of $3 to $4). Tiger